A Phase 4 interventional study of Erythropoietin in Autoimmune Encephalitis, sponsored by Seoul National University Hospital. Withdrawn at 1 site in Korea, Republic of. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2021-09-29.
Sponsored by Seoul National University Hospital · Phase 4, Interventional, and Treatment
This study evaluates the efficacy of erythropoietin in refractory autoimmune encephalitis. Ten patients will receive 100 IU/kg of erythropoietin 3 times a week for 12 weeks.
Erythropoietin can improve the refractory autoimmune encephalitis. Erythropoietin has tissue-protective effect via activation of Janus kinase (JAK)-2, signal transducer and activator of transcription (STAT)-5 pathway and NF-kappa B pathway. The activation of JAK-2 and STAT-5 promote hemoglobin synthesis and facilitate cell cycle progression. Also, NF-kappa B pathway inhibition regulates pro-inflammatory cytokine production.
We expect that erythropoietin may lead to improve the symptoms and outcome of autoimmune encephalitis.
283 studies on the registry are indexed under Encephalitis; 55 are open to participants now.
Browse Encephalitis studies →Seoul National University Hospital is the lead sponsor of 1,860 studies on the registry; 275 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Erythropoietin injection: three times per a week, 100 IU/kg for each patients Trade name: epokine prefilled injection
Drug: Erythropoietin
three times per a week 100IU / k
Also known as: Epokine prefilled injection
Change from Baseline modified Rankin Scale (mRS) at 12th week
Favorable outcome is an improvement of mRS score.
Time frame: 2nd week, 12th week
Adverse effect
Common terminology criteria for adverse events (CTCAE) 4.0
Time frame: 2nd week, 4th week, 8th week, 12th week
Quality of Life in Epilepsy Inventory (QOLIE) -31
Time frame: 2nd week, 4th week, 8th week, 12th week
Mini-Mental State Examination (MMSE)
Time frame: 2nd week, 4th week, 8th week, 12th week
Plan to share: No
No publications or documents are linked to this record.
This study is withdrawn, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seoul National University Hospital